

Educational Objectives

- GOAL:** To provide comprehensive and up-to-date information concerning the use of angiotensin-converting enzyme inhibitors in managed care.
- TARGET AUDIENCE:** This activity is designed for pharmacists and physicians, as well as managed care decision makers, healthcare policy planners, and pharmacy and therapeutics committee members.
- LEARNING OBJECTIVES:** Upon completion of this program, the participant should be able to:
1. Describe the etiology and pathophysiology including sequelae.
 2. Identify signs and symptoms.
 3. Discuss epidemiologic considerations, such as incidence, prevalence, demographics, and other contributing factors.
 4. Analyze pharmacokinetic differences as they relate to age, gender, genetic factors, environment and cultural factors, disease states, alcohol consumption, and smoking.
 5. Evaluate pertinent physical assessment parameters, laboratory studies, diagnostic tests, serum drug concentrations, and pharmacokinetics for abnormal findings.
 6. Apply general principles of clinical pharmacokinetics including calculations as required.
 7. Describe the mechanism of action of pharmacologic and non-pharmacologic interventions employed in the treatment.
 8. Analyze factors that should be considered when choosing pharmacologic and nonpharmacologic therapy.
 9. Identify potential or actual drug interactions.
 10. Recognize common adverse effects of pharmacologic treatments.
 11. Evaluate present pharmacologic and nonpharmacologic treatment for problems (eg, lack of appropriate indications, dose, etc).
 12. Suggest recommendations for optimizing pharmacologic and nonpharmacologic treatment to achieve algorithms including JNC-VI.
 13. Use the Problem List and SOAP Note format to analyze, synthesize, and prioritize pertinent data in order to develop a plan of care.
 14. Develop a detailed education plan for the patient including necessary lifestyle changes, medication counseling information, specific counseling techniques, and adherence strategies.
 15. Analyze psychosocial factors that may affect patient adherence with both pharmacologic and nonpharmacologic therapy.
 16. Describe the healthcare provider's role relative to psychosocial factors.
 17. Evaluate the pharmacoeconomic considerations relative to the patient's plan of care.
 18. Summarize therapeutic, pathophysiologic, and disease management concepts for a given condition utilizing a key points format.

College of Pharmacy
Office of the Dean
3 North Dunlap, Suite 201
Memphis, TN 38163
(901) 448-6036 • FAX (901) 448-7053

Dear Colleagues:

This Special Report supplement to *The American Journal of Managed Care* will provide healthcare providers and administrators with an update on the class effects of angiotensin-converting enzyme (ACE) inhibitors and issues related to pharmacoeconomics and clinical and humanistic outcomes in the use of ACE inhibitors through 2 manuscripts and 9 case studies. The manuscripts by Domenic A. Sica, MD on class effects of ACE inhibitors and C. E. Reeder, RPh, PhD; Greta A. Gourley, PhD, PharmD; Pamala Reed, DPH, MPH; and J. Doug Wurtzbacher, PharmD on the pharmacoeconomics of ACE inhibitors will provide current background information relative to this class of agents.

A panel of healthcare providers, educators, and graduate students representing cardiology, internal medicine, family medicine, clinical pharmacy, nurse practitioners, and healthcare administrators were convened to develop 9 cases that explore the utilization of ACE inhibitors in managed care.

After reading the 2 manuscripts and each case, participants of this educational supplement should be able to develop and prioritize a list of problems for each case, write a SOAP (Subjective, Objective, Assessment Plan) Note, and answer the case questions. This program provides continuing education credit for pharmacists through the University of Tennessee College of Pharmacy and for medical practitioners through Johns Hopkins University School of Medicine. Our 2 Universities are extremely pleased to have worked together to develop this supplement. There are 13 hours of continuing education credit available. Participants may elect to participate in all 13 hours or only 1 hour.

Each of the cases is designed using the same case format and are categorized as Level 1, 2, or 3 based on their degree of difficulty. Participants are then able to identify the level of knowledge and problem-solving required to design a pharmaceutical plan as well as answer pertinent questions. Each case includes a blank problem list and SOAP Note that participants should complete before answering the case questions. Completed problem lists and SOAP Notes are provided at the end of the supplement in order that participants can compare their notes with those generated by the expert panel.

A Universal Set of Educational Objectives and a glossary of acronyms and abbreviations used in the supplement are included as well. All case questions include the number of the educational objective to which the questions refer. We hope that all participants find the materials helpful in their practice.

We would like to thank our colleagues at Novartis for providing the unrestricted educational grant to support this Special Report supplement.

Sincerely,



Dick R. Gourley, PharmD
Professor and Dean



Greta Gourley, PhD, PharmD
Associate Professor

This program has been supported by an unrestricted educational grant from **Novartis Pharmaceutical Corporation**.

The content of this Special Report supplement may include information regarding the use of products that may be inconsistent with or outside labeling for these products in the United States. Physicians and pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.